Arvinas, Bayer Form Human Disease Collaboration, Agricultural Venture
June 04 2019 - 07:38AM
Dow Jones News
By Colin Kellaher
Arvinas Inc. (ARVN) Tuesday said it will collaborate with Bayer
AG (BAYN.XE) to develop new human therapeutics for patients with
cardiovascular, oncological and gynecological diseases and will
launch a joint venture with the German chemical-and-pharmaceutical
company to develop targeted protein degraders for agricultural
applications.
Arvinas, a New Haven, Conn., biopharmaceutical company, said the
deal includes more than $110 million in upfront cash and committed
funding for the collaboration, the venture and a direct equity
investment by Bayer.
Trading in shares of Arvinas, which closed Monday at $20.05, was
halted premarket Tuesday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 04, 2019 07:23 ET (11:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bayer Aktiengesellschaft (PK) (USOTC:BAYRY)
Historical Stock Chart
From Mar 2023 to Mar 2024